Nuvation Bio (NUVB) Income towards Parent Company (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Income towards Parent Company of $5.4 million for Q1 2026, up 110.14% year-over-year from $2.6 million in Q1 2025, and up 114.75% quarter-over-quarter from -$36.6 million in Q4 2025.
Nuvation Bio (NUVB) Income towards Parent Company (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Income towards Parent Company for 7 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company rose 110.14% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at -$146.0 million (up 75.92% YoY), while the FY2025 annual figure was -$204.6 million, up 63.97% from the prior year.
- Income towards Parent Company advanced to $5.4 million in Q1 2026 per NUVB's latest filing, from -$36.6 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $5.4 million in Q1 2026 and bottomed at -$462.5 million in Q2 2024.
- Historically, Income towards Parent Company has averaged -$55.7 million across 5 years, with a median of -$27.2 million in 2022.
- Annual changes were most pronounced in 2024 — Income towards Parent Company slumped 2140.76% — and 2026, when it jumped 110.14%.
- Nuvation Bio's Income towards Parent Company stood at -$20.8 million in 2022, then jumped by 33.86% to -$13.8 million in 2023, then slumped by 258.63% to -$49.4 million in 2024, then gained by 25.99% to -$36.6 million in 2025, then surged by 114.75% to $5.4 million in 2026.
- Business Quant data shows NUVB's Income towards Parent Company at $5.4 million in Q1 2026, -$36.6 million in Q4 2025, and -$55.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.84 Mn |
| Mar 31, 2026 | 5.40 Mn |
| Dec 31, 2025 | -36.59 Mn |
| Sep 30, 2025 | -55.79 Mn |
| Jun 30, 2025 | -59.01 Mn |
| Mar 31, 2025 | -53.24 Mn |
| Dec 31, 2024 | -49.45 Mn |
| Sep 30, 2024 | -41.21 Mn |
| Jun 30, 2024 | -462.49 Mn |
| Mar 31, 2024 | -14.79 Mn |
| Dec 31, 2023 | -13.79 Mn |
| Sep 30, 2023 | -19.65 Mn |
| Jun 30, 2023 | -20.64 Mn |
| Mar 31, 2023 | -21.73 Mn |
| Dec 31, 2022 | -20.85 Mn |
| Sep 30, 2022 | -27.20 Mn |
| Jun 30, 2022 | -34.86 Mn |
| Mar 31, 2022 | -21.29 Mn |
| Dec 31, 2021 | -25.13 Mn |
| Sep 30, 2021 | -21.98 Mn |